Floatz Rating
CC46/100
Confidence
Indicative
Sponsor
Global Blood Therapeutics
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
31High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02989168CT.gov Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at Rest | — | Terminated | — | — | — |
NCT02846324CT.gov Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Idiopathic Pulmonary Fibrosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Voxelotor (this asset) | Global Blood Therapeutics | P2 | CC · 46 |
| Pirfenidone | Endeavor Biomedicines, Inc. | P4 | A |
| Acetylcysteine | Endeavor Biomedicines, Inc. | P4 | BBB |
| Nintedanib | Mannkind Corporation | P4 | BBB |
| Prednisone | Fondation Hôpital Saint-Joseph | P3 | BB |
| Nerandomilast | Boehringer Ingelheim | P3 | BB |
| hsk44459 | Haisco Pharmaceutical Group Co., Ltd. | P3 | BB |
| Sildenafil | Hoffmann-La Roche | P4 | BB |
| hec585 | Sunshine Lake Pharma Co., Ltd. | P3 | B |
+42 more in the Idiopathic Pulmonary Fibrosis cohort
Other indications for Voxelotor
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Sickle Cell Disease | — | P4 | B · 57 |
| Ulcer Of Lower Limbs | — | P3 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Voxelotor in Idiopathic Pulmonary Fibrosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/voxelotor-idiopathic-pulmonary-fibrosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →